Preview

FARMAKOEKONOMIKA. Modern Pharmacoeconomic and Pharmacoepidemiology

Advanced search

COST EFFECTIVENESS OF ORAL PERICALCITOL IN PATIENTS WITH STAGE III-IV CHRONIC KIDNEY DISEASE AND SECONDARY HYPERPARATHYREOSIS

Full Text:

Abstract

results of clinical trials demonstrate that selective vitamin D receptor agonist paricalcitoldecreases proteinuria in patients with chronic kidney disease (CKD) and hyperparathyreosis.

About the Author

A. V. Rudakova
Sankt-Petersburg Chemical-Pharmaceutical Academy
Russian Federation

Professor Saint-Petersburg chemical-pharmaceutical Akademy.St. Petersburg, Russia tel: (812) 541-86-74



References

1. Agarwal R., Acharya M., Tian J., et al. Antiproteinuric effect of oral paricalcitol in chronic kidney disease. Kidney International. 2005; 68: 2823–2828.

2. Palmer AJ, Annemans L, Roze S, Lamotte M, Lapuerta P, Chen R, et al. Cost-effectiveness of early irbesartan treatment versus control (standard antihypertensive medications excluding ACE inhibitors, other angiotensin-2 receptor antagonists, and dihydropyridine calcium channel blockers) or late irbesartan treatment in patients with type 2 diabetes, hypertension, and renal disease. Diabetes Care. 2004.– Vol. 27. № 8. P. 1897-903.

3. Рудакова А.В. Фармакоэкономические аспекты терапии алискиреном артериальной гипертензии у пациентов с сахарным диабетом 2 типа и нефропатией. Клиническая фармакология и терапия. 2009. № 4. С. 48-50.

4. Приложения к Генеральному тарифному соглашению по тарифам на медицинскую помощь (медицин ские услуги) и условиям оплаты медицинской помощи, оказываемой в рамках действующей Территори альной программы обязательного медицинского страхования граждан Российской Федерации в Санкт-Петербурге на 2011 г. (www.spboms.ru).

5. Alborzi P., Patel N., Peterson C., et al. Paricalcitol reduces albuminuria and inflammation in chronic kidney disease. A randomized double-blind pilot trial. Hypertension 2008; 52: 249-255.

6. de Zeeuw D., Agarwal R., Amdahl M., et al. Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet 2010; 376 (9752): 1543-51.

7. Brancaccio D., Cozzolino M., Cannella G., et al. Secondary hyperparathyroidism in chronic dialysis patients: results of the Italian FARO Survey on treatment and mortality. Blood Purif. 2011; 32 (2): 124-132.

8. Mazzaferro S., Brancaccio D., Messa P., et al. Management of secondary hyperparathyroidism in Italy: results of the Italian FARO survey. J. Nephrol. 2011; 24 (2): 225-35.

9. Brown G.C., Brown M.M., Sharma S., et al. Quality of life associated with diabetes mellitus in an adult population. J. Diabetes Complications 2000;14 (1): 18-24.

10. Tengs T.O., Wallace A. One thousand health-related quality-oflife estimates. Med Care 2000; 38 (6): 583-637.

11. Kelley K., Aricak O., Light R., Agarwal R. Proteinuria is a determinant of quality of life in diabetic nephropathy: modeling lagged effects with path analysis. Am. J. Nephrol. 2007; 27 (5): 488-94.


For citation:


Rudakova A.V. COST EFFECTIVENESS OF ORAL PERICALCITOL IN PATIENTS WITH STAGE III-IV CHRONIC KIDNEY DISEASE AND SECONDARY HYPERPARATHYREOSIS. FARMAKOEKONOMIKA. Modern Pharmacoeconomic and Pharmacoepidemiology. 2012;5(2):13-16. (In Russ.)

Views: 253


ISSN 2070-4909 (Print)
ISSN 2070-4933 (Online)